<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183738</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10-i2-DEFT</org_study_id>
    <secondary_id>18Q065</secondary_id>
    <nct_id>NCT04183738</nct_id>
  </id_info>
  <brief_title>Inflammation and Co-Infections in D²EFT</brief_title>
  <acronym>i2-D²EFT</acronym>
  <official_title>The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Frederick National Laboratory for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNITAID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      i2-D²EFT substudy is an observational cohort nested within the parent D²EFT study
      (NCT03017872). D²EFT goal is to compare the standard of care second-line antiretroviral
      therapy in people living with HIV whose first-line non nucleoside reverse transcriptase-based
      regimen failed, to two simpler regimens. Approximately 1,000 participants will be enrolled in
      D²EFT.

      Commencing a second-line ART is an important moment when the level of inflammation in
      participants may be elevated due to first-line ART failure; this level of inflammation should
      then decrease with the commencement of a new second-line treatment and would be expected to
      normalise by 48 weeks of second-line treatment, if successful.

      The investigators propose to study other factors which can influence the decrease of
      inflammation. The investigators hypothesise that co-infections may play a role in persistent
      inflammation. The key-infections of interest will be common frequent infections encounter
      throughout the world: Human Herpes virus 8, Epstein-Barr virus, Cytomegalovirus and Human
      papillomavirus, tuberculosis, malaria and other key opportunistic infections. Possible
      changes of level of inflammation (using the serum level of Interleukin 6) in approximately
      200 participants of the D²EFT study will be investigated and measured. The hypothesis is that
      the presence of other infections than HIV may influence the level of inflammation in
      participants in therapeutic success.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      i2-D²EFT substudy an observational cohort nested within the parent open label phase III/IV
      randomised controlled trial of simplified second-line therapy, D²EFT (NCT03017872).
      Participants consenting to D²EFT study will be randomised within the three arms: either
      ritonavir-boosted darunavir plus two nucleosides or dolutegravir plus two predetermined
      nucleosides (tenofovir disoproxil fumarate plus lamivudine or emtricitabine) or
      ritonavir-boosted darunavir plus dolutegravir. Enrolment into the i2-D²EFT substudy is
      voluntary and optional for participants in D²EFT. Parameters relevant to i2-D²EFT substudy
      including demographics, arm of randomised ART, HIV history, physical examination,
      immunological and virological results, episodes of co-infections and adverse events due to
      any infection or malignancies at required time points will be collected as part of D²EFT
      study. Substudy specific assessments performed at baseline and at weeks 48 include sample
      collection for IL-6 dosage plus EBV/CMV/HHV8 testing, and optional anal/cervical HPV
      screening.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">February 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Observational cohort nested within the parent open label phase III/IV randomised controlled trial of simplified second-line therapy, D²EFT.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in IL-6 level at week 48</measure>
    <time_frame>At week 0 and week 48</time_frame>
    <description>To compare the change of a biomarker of inflammation (IL-6) in participants who achieve HIV virological suppression (defined as peripheral blood viral load below 50 copies/mm3 at week 48) across the three study arms according to the presence (or not) of active key-co-infections (HHV8, EBV, CMV, HPV) at baseline and week 48, and the occurrence (or not) within these 48 weeks of any infection (co-infections or opportunistic infections).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of presence/absence of active key co-infections at week 48</measure>
    <time_frame>At week 0 and week 48</time_frame>
    <description>Active key-co-infections (HHV8, EBV, CMV, HPV) at baseline and week 48, and the occurrence (or not) within these 48 weeks of any infection (co-infections or opportunistic infections).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HHV8, EBV and CMV and of cervical and anal HPV</measure>
    <time_frame>At week 0</time_frame>
    <description>To describe the prevalence of HHV8, EBV and CMV (defined by serological assays) and of cervical and anal HPV (defined by tissue HPV deoxyribonucleic acid (DNA) detection) at baseline, in the D2EFT cohort, by geographic region, route of HIV transmission, and other demographic and disease variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of active HHV8, EBV and CMV</measure>
    <time_frame>At week 48</time_frame>
    <description>To compare the occurrence of active HHV8, EBV and CMV (defined by a detectable peripheral blood viral load) in participants with and without HIV virological suppression at 48 weeks, across the three arms of D²EFT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rates of detection of cervical and anal HPV infection at week 48</measure>
    <time_frame>At week 0 and week 48</time_frame>
    <description>To compare rates of detection of cervical and anal HPV infection (defined by tissue HPV DNA detection) between baseline and week 48 in participants with and without HIV virological suppression at 48 weeks across the three arms of D²EFT.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV-infection/Aids</condition>
  <condition>Human Herpesvirus 4 Infections</condition>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Human Herpesvirus 8 Infection</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>darunavir/ritonavir 800/100mg + 2 NRTIs po od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darunavir/ritonavir 800/100mg + dolutegravir 50mg po od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dolutegravir 50mg + tenofovir + emtricitabine or lamivudine po od</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRTIs</intervention_name>
    <description>In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.
In D2N arm, NRTIs are predetermined.</description>
    <arm_group_label>D2N</arm_group_label>
    <arm_group_label>SOC</arm_group_label>
    <other_name>Nucleoside/Nucleotide Reverse Transcription Inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>800mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>DOL</arm_group_label>
    <arm_group_label>SOC</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>DOL</arm_group_label>
    <arm_group_label>SOC</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>50mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>D2N</arm_group_label>
    <arm_group_label>DOL</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfil the eligibility criteria for D²EFT randomisation;

          -  Being able to give a written informed consent for the i2-D²EFT sub-study.

        Exclusion Criteria:

          -  Unwilling to comply with the i2-D²EFT protocol requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Polizzotto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute, UNSW Sydney, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle Papot, MD</last_name>
    <phone>+61 9385 0902</phone>
    <email>epapot@kirby.edu.unsw.au</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>IL-6</keyword>
  <keyword>EBV</keyword>
  <keyword>CMV</keyword>
  <keyword>HHV8</keyword>
  <keyword>HPV</keyword>
  <keyword>inflammation</keyword>
  <keyword>co-infections</keyword>
  <keyword>opportunistic infections</keyword>
  <keyword>AIDS and non-AIDS defining cancers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

